Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473600 | 1.00 | DPP4 (0.39) | DPP4IDO1EPHX1 | |
| SCHEMBL4823652 | 0.79 | IDO1 (0.36) | DPP4IDO1EPHX1 | |
| SCHEMBL13814727 | 0.79 | IDO1 (0.36) | DPP4IDO1EPHX1 | |
| SCHEMBL3303561 | 0.77 | IDO1 (0.35) | DPP4IDO1EPHX1 | |
| SCHEMBL10431094 | 0.76 | CSNK1E (0.51) | EPHX1 | |
| SCHEMBL4890232 | 0.73 | ADRA2A (0.39) | — | |
| SCHEMBL4522362 | 0.72 | CSNK1E (0.55) | DPP4IDO1 | |
| SCHEMBL3352638 | 0.72 | BACE1 (0.44) | — | |
| SCHEMBL13817892 | 0.72 | CSNK1E (0.55) | DPP4IDO1 | |
| SCHEMBL3351390 | 0.71 | BACE1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299117-A1 | Hydroxypropylaimines | PHARMACIA & UPJOHN COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-20070299117-A1 | Hydroxypropylaimines | PHARMACIA & UPJOHN COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-20070225374-A1 | Hydroxypropyl Amides for the Treatment of Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225374-A1 | Hydroxypropyl Amides for the Treatment of Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7262208-B2 | Hydroxypropyl amides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262208-B2 | Hydroxypropyl amides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299117-A1 | Hydroxypropylaimines | BACE1, APP, BACE2 | DPP4 343/4885IDO1 1977/4885EPHX1 348/4885 |
| US-20070225374-A1 | Hydroxypropyl Amides for the Treatment of Alzheimer's Disease | BACE1, APP, BACE2 | DPP4 118/4885IDO1 2083/4885EPHX1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.